<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000962</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 164</org_study_id>
    <secondary_id>00744</secondary_id>
    <nct_id>NCT00000962</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of BI-RG-587 in HIV-Infected Patients</brief_title>
  <official_title>An Open Label, Staggered Rising Dose Cohort Study Assessing Safety, Tolerance, and Activity of BI-RG-587 in Patients With HIV Infection (CD4+ Cell Count &lt; 400 Cells/mm3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To assess the safety and tolerance of multiple oral doses of Nevirapine (BI-RG-587). To&#xD;
      generate data on the pharmacokinetics and dose proportionality of Nevirapine with multiple&#xD;
      dosing. To characterize the pattern of virological activity in vivo. Improvement in&#xD;
      virological end points will be examined for association with dose and absorption. To&#xD;
      determine whether development of resistance is reflected in return of virological activity&#xD;
      and, if so, when markers reflect this resistance. To determine if improvements of&#xD;
      immunological endpoints are detectable in the number of patients studied. A compound free of&#xD;
      the toxic effects of nucleoside chain terminators such as zidovudine (AZT) may have an&#xD;
      advantage over currently available treatments for HIV infection. Such a compound has further&#xD;
      advantages if it is active against AZT-resistant isolates. Nevirapine (BI-RG-587) has shown&#xD;
      in vitro inhibitory activity against HIV-1 reverse transcriptase (RT). The molecular&#xD;
      mechanism of the RT inhibitory effect is hypothesized to be non-competitive inhibition due to&#xD;
      its binding to an RT site distinct from those for the RNA template primer, the&#xD;
      deoxynucleotide triphosphate or the RNase H catalytic site.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A compound free of the toxic effects of nucleoside chain terminators such as zidovudine (AZT)&#xD;
      may have an advantage over currently available treatments for HIV infection. Such a compound&#xD;
      has further advantages if it is active against AZT-resistant isolates. Nevirapine (BI-RG-587)&#xD;
      has shown in vitro inhibitory activity against HIV-1 reverse transcriptase (RT). The&#xD;
      molecular mechanism of the RT inhibitory effect is hypothesized to be non-competitive&#xD;
      inhibition due to its binding to an RT site distinct from those for the RNA template primer,&#xD;
      the deoxynucleotide triphosphate or the RNase H catalytic site.&#xD;
&#xD;
      This is a staggered dose escalation cohort trial which examines the safety, tolerance,&#xD;
      pharmacokinetics and activity of Nevirapine (BI-RG-587) in patients with HIV infection.&#xD;
      Groups of 10 patients must have completed 4 weeks of therapy without requiring dose&#xD;
      interruption before the next dosage level can be initiated. All 10 patients must be enrolled&#xD;
      at a lower dosage level before the next dosage level can be initiated. Patients discontinue&#xD;
      antiretroviral therapy, after signing informed consent, 28 days prior to receipt of a first&#xD;
      dose of Nevirapine. Screening lab tests, including p24 antigen and plasma viremia, and CD4+&#xD;
      cell count determination are performed 21 days prior to drug dosing in Part I. Patients are&#xD;
      notified of screening laboratory measures that exclude them from study participation. Upon&#xD;
      such notification patients have the option to resume prior antiretroviral therapy or to&#xD;
      repeat those values in one week. Part II consists of two 8-hour intensive blood sampling&#xD;
      periods plus frequent trough value blood samplings. Safety, trough value blood sampling, and&#xD;
      activity assessments are performed in Part III. An assessment of dose-tolerance and of&#xD;
      activity is made in Study Week 12 in order that patients may continue Nevirapine chronic&#xD;
      therapy for an additional 12 weeks. The Final Visit in Part IV takes place on Study Week 24&#xD;
      to complete the trial. Patients who complete 24 weeks are offered the option to continue on&#xD;
      Nevirapine chronic therapy at the initial or an altered dose on a separate open-label&#xD;
      protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Pentamidine or dapsone prophylaxis for Pneumocystis carinii pneumonia (PCP) in&#xD;
             patients with a CD4+ cell count = or &lt; 200 cells/mm3.&#xD;
&#xD;
          -  Antifungal prophylaxis with oral fluconazole or ketoconazole.&#xD;
&#xD;
          -  Antiviral prophylaxis with a maximum of 1 gram of oral acyclovir per day.&#xD;
&#xD;
          -  Acute therapy for intercurrent infections so long as that therapy is not an excluded&#xD;
             medication of an excluded opportunistic infection.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Positive HIV antibody test results by ELISA.&#xD;
&#xD;
          -  Average of CD4+ cell count at 60 and at 21 days prior to study beginning = or &lt; 400&#xD;
             cells/mm3.&#xD;
&#xD;
          -  Seven of 10 patients in each treatment arm must have p24 antigen levels = or &gt; 70&#xD;
             pg/ml (&gt; 50 pg/ml at U. of Mass. site only) or be plasma viremic.&#xD;
&#xD;
          -  Preserved hematologic, hepatic, and renal function as defined by required lab values.&#xD;
&#xD;
          -  Ambulatory performance score of = or &gt; 70 Karnofsky.&#xD;
&#xD;
          -  Ability to voluntarily provide written informed consent prior to treatment.&#xD;
&#xD;
          -  Willingness and ability to follow protocol requirements.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active cytomegalovirus disease.&#xD;
&#xD;
          -  Toxoplasmic encephalitis requiring suppressive therapy.&#xD;
&#xD;
          -  Mycobacteriosis requiring maintenance chemotherapy.&#xD;
&#xD;
          -  Visceral Kaposi's sarcoma requiring chemotherapy and/or irradiation.&#xD;
&#xD;
          -  Malignancy other than Kaposi's sarcoma or limited cutaneous basal cell carcinoma.&#xD;
&#xD;
          -  More than mild diarrhea (defined as more than transient or &gt; 4 loose stools per day).&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        The following medications / substances may NOT be ingested up to one hour before or 4 hours&#xD;
        after a Nevirapine dose:&#xD;
&#xD;
          -  Antacids (particularly those containing calcium carbonate).&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Carafate.&#xD;
&#xD;
          -  Cholestyramine resin.&#xD;
&#xD;
          -  Alcohol and alcohol-containing substances.&#xD;
&#xD;
          -  Benzodiazepines (diazepam, triazolam).&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any approved or investigational antiretroviral, immunosuppressive, or cytotoxic drugs.&#xD;
&#xD;
          -  Glucocorticoids and steroid hormones (including oral contraceptives).&#xD;
&#xD;
          -  Dicumarol, warfarin, and other anticoagulant medications.&#xD;
&#xD;
          -  Nitroglycerin.&#xD;
&#xD;
          -  Digitoxin.&#xD;
&#xD;
          -  Valproic acid.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Doxycycline.&#xD;
&#xD;
          -  Chloramphenicol.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Any sulfonamide medications.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  History of clinically important disease other than HIV infection defined by the&#xD;
             investigator as possibly putting the patient at risk during study participation.&#xD;
&#xD;
          -  Conditions listed in Exclusion Co-Existing Conditions and symptoms.&#xD;
&#xD;
          -  Having received any approved or investigational antiretroviral, immunosuppressive, or&#xD;
             cytotoxic drugs or any other experimental drug with 4 weeks of study entry.&#xD;
&#xD;
          -  A positive zidovudine (AZT) detection assay performed 7 days prior to drug dosing will&#xD;
             exclude patients from study participation.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Any approved or investigational antiretroviral, immunosuppressive or cytotoxic drugs.&#xD;
&#xD;
          -  Glucocorticoids and steroid hormones (including oral contraceptives).&#xD;
&#xD;
          -  Dicumarol, warfarin, and other anticoagulant drugs.&#xD;
&#xD;
          -  Nitroglycerin. Digitoxin.&#xD;
&#xD;
          -  Valproic acid.&#xD;
&#xD;
          -  Tolbutamide.&#xD;
&#xD;
          -  Doxycycline.&#xD;
&#xD;
          -  Chloramphenicol.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Antiepileptics (phenobarbital and other barbiturates).&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole (Bactrim).&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Patients whose use of alcohol or drugs is sufficient to impair compliance with&#xD;
             protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Massachusetts Med Ctr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Greenough TC. Quantitative virology: the experience during the nevirapine phase I/II trials. ACTG 164/168 Study Team. Int Conf AIDS. 1992 Jul 19-24;8(2):B192 (abstract no PoB 3610)</citation>
  </reference>
  <reference>
    <citation>Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995 Mar;171(3):537-45. doi: 10.1093/infdis/171.3.537.</citation>
    <PMID>7533197</PMID>
  </reference>
  <reference>
    <citation>Havlir D. Antiviral activity of nevirapine at 400 mg in p24 antigen positive adults. ACTG 164 and 168 Study Teams. Int Conf AIDS. 1993 Jun 6-11;9(1):69 (abstract no WS-B26-1)</citation>
  </reference>
  <reference>
    <citation>Richman DD. Loss of nevirapine activity associated with the emergence of resistance in clinical trials. The ACTG 164/168 Study Team. Int Conf AIDS. 1992 Jul 19-24;8(2):B183 (abstract no PoB 3576)</citation>
  </reference>
  <reference>
    <citation>Hattox S. Pharmacokinetics of nevirapine alone and in combination with zidovudine. The ACTG 164/168 Study Team. Int Conf AIDS. 1992 Jul 19-24;8(2):B185 (abstract no PoB 3591)</citation>
  </reference>
  <reference>
    <citation>Cheeseman SH, Murphy RL, Saag MS, Havlir D. Safety of high dose nevirapine (NVP) after 200 mg/d lead-in. ACTG 164/168 Study Team. Int Conf AIDS. 1993 Jun 6-11;9(1):487 (abstract no PO-B26-2109)</citation>
  </reference>
  <reference>
    <citation>Cheeseman SH. Nevirapine (NVP) alone and in combination with zidovudine (ZDV): safety and activity. The ACTG 164/168 Study Team. Int Conf AIDS. 1992 Jul 19-24;8(1):Mo15 (abstract no MoB 0053)</citation>
  </reference>
  <reference>
    <citation>Zhang H, Dornadula G, Wu Y, Havlir D, Richman DD, Pomerantz RJ. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. J Virol. 1996 Jan;70(1):628-34. doi: 10.1128/JVI.70.1.628-634.1996.</citation>
    <PMID>8523584</PMID>
  </reference>
  <reference>
    <citation>Murphy RL, Montaner J. Nevirapine: A review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs. 1996;5(9): 1183-1199</citation>
  </reference>
  <reference>
    <citation>Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):141-51.</citation>
    <PMID>7530585</PMID>
  </reference>
  <verification_date>December 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 1, 2008</last_update_submitted>
  <last_update_submitted_qc>August 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2008</last_update_posted>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Nevirapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

